Otros idiomas NeuroMetrix, Inc.

Acciones

NURO

US6412558800

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
4,44 ^USD	+1,60 %		+2,54 %	+23,33 %

19/04	Neurometrix, Inc. Nombra a Joshua S. Horowitz director de clase III en el Consejo de Administración	CI
14/03	NeuroMetrix, Inc. Anuncia la publicación de un estudio que demuestra que DPNCheck diagnostica con precisión la neuropatía diabética periférica	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Sector Update: Health Care Stocks Advance Late Afternoon	19/04
Sector Update: Health Care Stocks Rise Friday Afternoon	19/04
NeuroMetrix Says Joshua Horowitz Joining Board, Terminates At-the-Market Equity Facility	19/04
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value	19/04
Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board	19/04
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	20/03
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	14/03
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	14/03
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia	13/03
Ephraim Fields Discloses his Views on NeuroMetrix	27/02
RS Fund Discloses its Views on NeuroMetrix	26/02
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights	22/02
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call	15/02
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	13/02
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	13/02
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024	08/01
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)	12/12
Neurometrix, Inc. Reports Encouraging Results from Pilot Clinical Trial of Quell®? in Post-Acute Covid-19 Syndrome (Long Covid)	12/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas NeuroMetrix, Inc.

Acciones

NURO

US6412558800

Otros idiomas

Filtros